Introduction {#s1}
============

Meta-analysis is a statistical method of combining the results of individual studies to obtain the most reliable conclusions [@pone.0099961-Egger1]. In clinical medicine, the power of meta-analysis is indispensable for building feasible and practical guidelines for the treatment of diseases. Although the use of meta-analysis in basic biomedical research is rare, the demand has been increasing because many researchers are working on genetically modified mice to examine the roles of genes in animal behavior and metabolism, and the results of the behavioral studies are not always consistent across research laboratories [@pone.0099961-Crabbe1]. Studies with positive results tend to be published in scientific journals with many readers, while those with negative results are easily overlooked because they are typically coupled with positive results and published in journals with fewer readers.

Melanin-concentrating hormone (MCH) is a 17-amino-acid cyclic neuropeptide that was originally isolated from teleost fish; in these fish, MCH causes the aggregation of melanosomes in the scales, which results in color changes [@pone.0099961-Kawauchi1]. MCH expression is restricted to the lateral hypothalamus of the brain, and MCH is not expressed outside of the brain. Analyses of the gene expressions in the hypothalamus of leptin-deficient mice have revealed the orexigenic effect of MCH in mammals [@pone.0099961-Qu1]. There are one or two G-protein-coupled receptors for MCH: humans express MCHR1 and MCHR2, whereas rodents express only MCHR1 [@pone.0099961-Saito1], [@pone.0099961-Pissios1]. In contrast to the restricted localization of MCH neurons in the lateral hypothalamic area and the zona incerta, MCH neurons send their projections broadly across the brain, and MCHR1 is also widely expressed in the brain [@pone.0099961-Saito2]. The broad projections of MCH neurons suggest that MCH signaling may be involved in the regulation of a wide array of behaviors [@pone.0099961-Pissios1].

Consistent with the orexigenic effect of the injection of MCH into the cerebral ventricles [@pone.0099961-Qu1], [@pone.0099961-Rossi1], [@pone.0099961-Gomori1], MCH-overexpressing mice exhibit increased food intake and develop mild obesity [@pone.0099961-Ludwig1]. Conversely, MCH-deficient mice and MCH neuron-ablated mice exhibit decreased food intake and lean phenotypes [@pone.0099961-Shimada1], [@pone.0099961-Alon1]. In addition to reduced food intake, increased energy expenditure also contributes to the lean phenotypes of MCH-deficient mice and MCH neuron-ablated mice [@pone.0099961-Shimada1]--[@pone.0099961-Kokkotou1]. Furthermore, MCHR1-deficient mice exhibit a lean phenotype and resistance to high-fat diet-induced obesity [@pone.0099961-Georgescu1]--[@pone.0099961-Marsh1]. These results indicate that the MCH-MCHR1 system works to accumulate energy in the body; therefore, MCH-receptor antagonists are currently believed to be attractive therapeutic targets for the treatment of obesity. However, it should be noted that the lean phenotypes of the MCH- and MCHR1-deficient mice have not always been replicated [@pone.0099961-Glier1], [@pone.0099961-Lalonde1], and increased food intake by MCH-deficient mice has also been reported [@pone.0099961-Kokkotou1].

In addition to metabolic parameters, MCH signaling appears to be involved in a variety of behavioral phenotypes. MCH- and MCHR1-deficient mice exhibit decreased non-REM sleep time [@pone.0099961-Willie1], [@pone.0099961-Ahnaou1], impaired olfactory function [@pone.0099961-Adams1], reduced responses to novelty [@pone.0099961-Lalonde1], suppressed startle responses [@pone.0099961-Lalonde1], and reduced sucrose preference [@pone.0099961-Duncan1]. Moreover, MCH signaling-deficient mice exhibit increased aggression [@pone.0099961-Adams1], alcohol preference [@pone.0099961-Duncan1], sexual motivation [@pone.0099961-Adams1], and sociability [@pone.0099961-Roy1]. However, the findings from behavioral analyses have not been consistent. For example, locomotor activity is one of the most commonly measured parameters, and the measurement of locomotor activity is highly automated; however, some groups have reported that MCH- or MCHR1-deficient mice exhibit increased locomotion [@pone.0099961-Kokkotou1], [@pone.0099961-Astrand1], [@pone.0099961-Zhou1], [@pone.0099961-Tyhon1], while others have reported no differences [@pone.0099961-Ahnaou1], [@pone.0099961-Adams1], [@pone.0099961-Adamantidis1], [@pone.0099961-Smith1]. Inconsistent findings regarding the roles of MCH signaling in anxiety behavior have also been reported; one study reported anxiolytic phenotypes among MCHR1-deficient mice [@pone.0099961-Roy1], whereas other groups have reported normal anxiety behavior in MCHR1-deficient mice [@pone.0099961-Adamantidis1], [@pone.0099961-Smith2]. These results prompted us to perform a meta-analysis to examine the contributions of MCH signaling to behavioral and metabolic parameters.

We performed a meta-analysis of the previously reported data regarding MCH signaling-deficient mice, MCH-deficient mice, and MCHR1-deficient mice. Because genetic background and sex affect behavioral and metabolic characteristics, we also performed separate meta-analyses segregated by background strain and sex.

Methods {#s2}
=======

Search Strategy {#s2a}
---------------

We performed an extensive electronic search to identify studies that had examined the effects of the deletion of MCH signaling on the behavioral phenotypes of mice. We searched PubMed (1948-Jan 2014) using the free-text search terms "melanin-concentrating hormone" or "melanin-concentrating hormone receptor" plus "knockout" or "deficient" on Jan 1, 2014. The first report about MCH signaling-deficient mouse was published in 1998 for MCH-deficient mouse [@pone.0099961-Shimada1], followed by the literature published in 2002 which was the first report about MCHR1-deficient mouse [@pone.0099961-Chen1]. Additional searches were performed using the first, last, and corresponding authors of any of the reports identified in the initial PubMed search. The search was restricted to papers written in English because paper translations were not feasible within the scope of this review. No other restrictions were placed on the search criteria. This search retrieved 164 studies. The reference lists of the included papers and recent review papers in the field were hand-searched along with back issues to identify additional references (See PRISMA flowchart; [Figure. 1](#pone-0099961-g001){ref-type="fig"}).

![Flow chart showing the selection process of articles and the number in each period.](pone.0099961.g001){#pone-0099961-g001}

Study Selection {#s2b}
---------------

A two-step procedure was used to identify the articles that were eligible for inclusion. First, the articles were assessed by reviewing their titles and abstracts to determine whether the articles met the following inclusion criteria: written in the English language; reported as an empirical article; used MCH-deficient or MCHR1-deficient mice; and included behavioral or metabolic experiments. These inclusion criteria were applied by two independent assessors, and the title and abstract reviews were conducted by same assessors. In cases in which the abstract provided insufficient information to make a final decision, the study was selected for full-text review. The full-text review was also conducted by two assessors. Next, the methodologies of the selected articles that were related to study quality were critically examined in full-text reviews. Studies that did not use wild-type littermates or wild-type animals from the same colony as the control mice were excluded. The parameter we used to index food intake was not normalized by body weight. The confirmation of the methodology was conducted by two assessors. The final decisions regarding inclusion were made by all of the present authors. Ultimately, 405 experiments from 33 studies were retained for the analysis. We did not include energy expenditure data in this study due to the inconsistency of the reported data ([Figure 2D](#pone-0099961-g002){ref-type="fig"} and [Table 1](#pone-0099961-t001){ref-type="table"} [@pone.0099961-Astrand1]).

![Funnel plot of effect sizes against sample sizes in overall meta-analysis.\
Black circles indicate behavioral or metabolic parameters.](pone.0099961.g002){#pone-0099961-g002}
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###### Results of meta-analysis.

![](pone.0099961.t001){#pone-0099961-t001-1}

  MCH Signaling Function                 Behavioral/Physiological/Biochemical Parameters   Sample Size   Number of Studies     r     95% Confidence Interval   P value vs. 0  
  ------------------------------------- ------------------------------------------------- ------------- ------------------- ------- ------------------------- --------------- --------
  Anxiety- and Mood-Related Behavior                                                                                                                                          
                                                       Elevated Plus Maze                      232              11           0.26             0.12                 0.38        \<0.05
                                           Elevated Plus Maze (Habituated Environment)         84                4           0.26             0.03                 0.46        \<0.05
                                                         Emergence Test                        42                2           −0.33            −0.02                −0.58       \<0.05
                                             Emergence Test (Habituated Environment)           42                4           −0.12            0.21                 −0.42        N.S.
                                                      Exploratory Behavior                     84                4           0.13             −0.10                0.34         N.S.
                                                        Forced Swim test                       68                2           0.23             −0.01                0.45         N.S.
                                                         Open Field Test                       330               9           0.26             0.15                 0.36        \<0.05
                                            Open Field Test (Habituated Environment)           168               8           0.31             0.15                 0.45        \<0.05
                                                      Response to Handling                     84                4           0.12             −0.11                0.34         N.S.
                                                       Response to Novelty                     84                4           0.25             0.03                 0.45        \<0.05
                                                  Response to Supine Restraint                 42                2           0.00             −0.32                0.32         N.S.
                                                        Startle Response                       42                2           0.35             0.04                 0.60        \<0.05
                                                   Stress−Induced Hyperthermia                 52                2           0.68             0.49                 0.81        \<0.05
  Body Weight and Energy Metabolism                                                                                                                                           
                                                           Body Length                         54                3           0.17             −0.12                0.44         N.S.
                                                        Body Temperature                       68                3           −0.64            −0.46                −0.76       \<0.05
                                                  Body Temperature (Dark Phase)                32                2           −0.18            0.20                 −0.51        N.S.
                                                 Body Temperature (Light Phase)                32                2           −0.52            −0.19                −0.75       \<0.05
                                                           Body Weight                         192              11           0.25             0.10                 0.39        \<0.05
                                                   Body Weight (High Fat Diet)                 90                5           0.49             0.30                 0.64        \<0.05
                                                            Fat Mass                           143              11           0.67             0.55                 0.76        \<0.05
                                                    Fat Mass (High Fat Diet)                   30                3           0.73             0.47                 0.88        \<0.05
                                                           Food Intake                         129               7           −0.26            −0.08                −0.43       \<0.05
                                                   Food Intake (High Fat Diet)                 116               7           −0.21            −0.02                −0.40       \<0.05
                                                            Lean Mass                          82                5           0.19             −0.04                0.41         N.S.
                                                    Lean Mass (High Fat Diet)                  16                2           0.17             −0.42                0.66         N.S.
                                                          Liver Weight                         24                1           0.70             0.42                 0.86        \<0.05
                                                       Oxygen Consumption                      24                3           −0.96            −0.90                −0.99       \<0.05
                                               Oxygen Consumption (High Fat Diet)              15                2           −0.98            −0.94                −1.00       \<0.05
  Cardiovascular System                                                                                                                                                       
                                                           Heart Rate                          16                1           −0.89            −0.71                −0.96       \<0.05
                                                     Heart Rate (Dark Phase)                   16                1           −0.86            −0.64                −0.95       \<0.05
                                                    Heart Rate (Light Phase)                   16                1           −0.68            −0.28                −0.88       \<0.05
                                                     Mean Arterial Pressure                    16                1           −0.85            −0.61                −0.95       \<0.05
                                               Mean Arterial Pressure (Dark Phase)             16                1           −0.24            0.29                 −0.66        N.S.
                                              Mean Arterial Pressure (Light Phase)             16                1           −0.08            0.43                 −0.55        N.S.
  Endocrinology and Lab Data                                                                                                                                                  
                                                     Blood Ethanol Kinetics                    72                4           −0.06            0.19                 −0.30        N.S.
                                                      Corticosterone Level                     52                3           −0.50            −0.25                −0.69       \<0.05
                                                         CRF Level in CE                       10                1           0.03             −0.61                0.65         N.S.
                                                        CRF Level in PVN                       10                1           0.55             −0.13                0.88         N.S.
                                                         Estrous Cycling                       20                1           −0.18            0.28                 −0.58        N.S.
                                                      Free Fatty Acid Level                    24                1           0.05             −0.36                0.44         N.S.
                                                          Ghrelin Level                        34                2           0.13             −0.23                0.46         N.S.
                                                          Glucose Level                        124               7           0.18             −0.01                0.36         N.S.
                                                  Glucose Level (High Fat Diet)                64                6           0.08             −0.21                0.35         N.S.
                                                          Insulin Level                        140               8           0.13             −0.05                0.30         N.S.
                                                  Insulin Level (High Fat Diet)                30                3           0.49             0.11                 0.75        \<0.05
                                                          Leptin Level                         130               8           0.57             0.42                 0.68        \<0.05
                                                  Leptin Level (High Fat Diet)                 30                3           0.65             0.33                 0.83        \<0.05
                                                   Leptin Level (per gram Fat)                 17                2           −0.17            0.39                 −0.65        N.S.
                                           Leptin Level (per gram Fat) (High Fat Diet)         36                4           0.51             0.16                 0.74        \<0.05
                                                    Liver Triglyceride Level                   24                1           0.60             0.26                 0.81        \<0.05
                                            Liver Triglyceride Level (High Fat Diet)           14                1           0.77             0.40                 0.92        \<0.05
                                                            T4 Level                           66                3           0.54             0.33                 0.70        \<0.05
                                                     Total Cholesterol Level                   24                1           1.00             1.00                 1.00        \<0.05
                                                       Triglyceride Level                      72                3           0.20             −0.05                0.42         N.S.
  Learning and Memory                                                                                                                                                         
                                                    Spatial Learning Function                  42                2           −0.21            0.12                 −0.49        N.S.
  Locomotion                                                                                                                                                                  
                                                       Locomotor Activity                      609              10           −0.18            −0.10                −0.26       \<0.05
                                               Locomotor Activity (High Fat Diet)              15                2           −0.93            −0.77                −0.98       \<0.05
                                                 Locomotor Activity (Dark Phase)               56                5           −0.59            −0.36                −0.75       \<0.05
                                         Locomotor Activity (Dark Phase) (High Fat Diet)       15                2           −0.87            −0.60                −0.96       \<0.05
                                                Locomotor Activity (Light Phase)               32                2           −0.30            0.07                 −0.60        N.S.
  Reward System                                                                                                                                                               
                                                       Alcohol Preference                      30                2           −0.59            −0.26                −0.79       \<0.05
                                                  Conditioned Place Preference                 14                1           0.66             0.20                 0.88        \<0.05
                                              Motor Activation by Psychostimulants             38                1           −0.44            −0.13                −0.66       \<0.05
                                                Sensitization to Psychostimulants              31                1           −0.11            0.28                 −0.46        N.S.
                                                       Sucrose Preference                      15                1           0.39             −0.15                0.75         N.S.
  Sensorimotor Function                                                                                                                                                       
                                                       Motor Coordination                      210              10           −0.11            0.03                 −0.25        N.S.
                                                            Olfaction                          13                1           0.60             0.08                 0.87        \<0.05
  Sleep-Wakefulness                                                                                                                                                           
                                                      Non-REM Sleep (24 h)                     68                3           0.54             0.33                 0.70        \<0.05
                                                   Non-REM Sleep (Dark Phase)                  52                3           0.50             0.24                 0.69        \<0.05
                                                   Non-REM Sleep (Light Phase)                 52                3           0.26             −0.03                0.51         N.S.
                                                        REM Sleep (24 h)                       52                3           −0.07            0.23                 −0.35        N.S.
                                                     REM Sleep (Dark Phase)                    52                3           0.01             −0.28                0.30         N.S.
                                                     REM Sleep (Light phase)                   52                3           −0.18            0.11                 −0.45        N.S.
                                                       Wakefulness (24 h)                      68                4           −0.51            −0.30                −0.68       \<0.05
                                                    Wakefulness (Dark Phase)                   52                3           −0.38            −0.10                −0.60       \<0.05
                                                    Wakefulness (Light Phase)                  52                3           −0.22            0.08                 −0.48        N.S.
  Social Behavior                                                                                                                                                             
                                                     Resident-Intruder Test                    16                1           −0.70            −0.32                −0.89       \<0.05
                                                      Male Mating Behavior                     10                1           −0.83            −0.43                −0.96       \<0.05
                                                     Social Interaction Test                   30                1           −0.36            0.00                 −0.64       \<0.05
  Aminergic and Peptidergic Signaling                                                                                                                                         
                                          Agouti-Related Protein Level in Hypothalamus         12                1           0.19             −0.43                0.69         N.S.
                                                         DA Level in NAc                       25                1           0.08             −0.32                0.46         N.S.
                                                        DAT Level in CPu                       24                2           −0.21            0.24                 −0.59        N.S.
                                                         DAT Level in GP                       10                1           0.00             −0.63                0.63         N.S.
                                                        DAT Level in NAc                       34                3           −0.21            0.18                 −0.54        N.S.
                                                         DAT Level in OT                       10                1           0.00             −0.63                0.63         N.S.
                                                         DAT Level in SN                       10                1           −0.16            0.53                 −0.72        N.S.
                                                        DAT Level in VTA                       10                1           −0.29            0.42                 −0.78        N.S.
                                                        D1R Level in CPu                       24                2           −0.03            0.41                 −0.45        N.S.
                                                         D1R Level in GP                       10                1           0.00             −0.63                0.63         N.S.
                                                        D1R Level in NAc                       34                3           0.47             0.11                 0.71        \<0.05
                                                         D1R Level in OT                       10                1           0.24             −0.46                0.76         N.S.
                                                         D1R Level in SN                       10                1           0.24             −0.46                0.76         N.S.
                                                        D1R Level in VTA                       10                1           0.63             0.00                 0.90        \<0.05
                                                        D2R Level in CPu                       24                2           0.52             0.12                 0.78        \<0.05
                                                         D2R Level in GP                       10                1           0.00             −0.63                0.63         N.S.
                                                        D2R Level in NAc                       34                3           0.32             −0.06                0.62         N.S.
                                                         D2R Level in OT                       10                1           0.63             0.00                 0.90        \<0.05
                                                         D2R Level in SN                       10                1           0.24             −0.46                0.76         N.S.
                                                        D2R Level in VTA                       10                1           0.24             −0.46                0.76         N.S.
                                                         NE Level in NAc                       25                1           0.08             −0.32                0.46         N.S.
                                                        NET Level in CPu                       10                1           −0.14            0.53                 −0.71        N.S.
                                                         NET Level in GP                       10                1           −0.78            −0.30                −0.95       \<0.05
                                                        NET Level in NAc                       20                2           −0.64            −0.24                −0.86       \<0.05
                                                         NET Level in OT                       10                1           −0.30            0.41                 −0.78        N.S.
                                                         NET Level in SN                       10                1           −0.62            0.02                 −0.90        N.S.
                                                        NET Level in VTA                       10                1           −0.51            0.18                 −0.86        N.S.
                                              Neuropeptide Y Level in Hypothalamus             12                1           0.19             −0.43                0.69         N.S.
                                                    NR1 Subunit Level in HPC                   36                3           0.58             0.28                 0.78        \<0.05
                                                    NR2A Subunit Level in HPC                  36                3           0.22             −0.16                0.53         N.S.
                                                    NR2B Subunit Level in HPC                  36                3           0.22             −0.16                0.53         N.S.
                                                  Orexin Level in Hypothalamus                 12                1           −0.19            0.43                 −0.69        N.S.
                                           Pro-Opiomelanocortin Level in Hypothalamus          12                1           0.79             0.40                 0.94        \<0.05
                                                        5HT Level in NAc                       25                1           0.08             −0.32                0.46         N.S.
                                                        5HT Level in PFC                       18                1           0.83             0.60                 0.94        \<0.05
                                                        5HTT Level in CPu                      10                1           0.00             −0.63                0.63         N.S.
                                                        5HTT Level in GP                       10                1           0.32             −0.39                0.79         N.S.
                                                        5HTT Level in NAc                      20                2           0.25             −0.26                0.65         N.S.
                                                        5HTT Level in OT                       10                1           0.60             −0.05                0.89         N.S.
                                                        5HTT Level in SN                       10                1           0.43             −0.27                0.83         N.S.
                                                        5HTT Level in VTA                      10                1           0.00             −0.63                0.63         N.S.
  Others                                                                                                                                                                      
                                                           Litter Size                         304               2           0.05             −0.06                0.17         N.S.
                                                          Mean Pup Mass                        304               2           0.09             −0.02                0.20         N.S.
                                                          Pup Mortality                        163               1           −0.14            0.01                 −0.29        N.S.

r = mean effect size, P value was calculated by Z test. CE, central amygdaloid nucleus; CPu, caudate-putamen; CRF, corticotropin-releasing factor; D1R, dopamine D1 receptor; D2R, dopamine D2 receptor; DA, dopamine; DAT, dopamine transporter; GP, globus pallidus; HPC, hippocampus; 5HTT, 5HT transporter; NAc, nucleus accumbens; NE, norepinephrine; NET, norepinephrine transporter; OT, olfactory tubercle; PFC, prefrontal cortex; PVN, paraventricular nucleus; SN, substantia nigra; VTA, ventral tegmental area.

Coding of the Variables {#s2c}
-----------------------

The effects of the deletion of MCH signaling on behavioral and metabolic phenotypes were derived by coding the performances in behavioral tests or the values that resulted from physiological and biochemical assays ([Table S1](#pone.0099961.s004){ref-type="supplementary-material"}). Regarding the behavioral phenotypes, the types of behavioral tests and the parameters of the behavioral tests were coded. Regarding the metabolic phenotypes, the units of the physiological and biochemical assays were coded. The behavioral and metabolic phenotypes were also coded for the background strain, sex, age, and sample size. Three background strains (C57BL/6, 129, and 129×C57BL/6) were coded, but the substrain, such as C57BL/6J, C57BL/6N, 129SvEv, and 129SvEvBrd, was not considered. In some cases, the sex or age was not described, and these cases were excluded from the separate meta-analyses.

Sensitivity Analysis {#s2d}
--------------------

To assess potential publication bias, the tendency that significant results are more likely to be published than negative results, funnel plots were first created for the overall meta-analysis and for each separate meta-analysis. Because larger study samples tend to provide better estimates of the true effect sizes, inverted funnel shapes should be observed when the effect sizes are plotted against the sample sizes. Further, the funnel plots were assessed for asymmetry using the Egger test [@pone.0099961-Egger1], [@pone.0099961-Egger2]. Asymmetry of funnel plots suggests the publication bias due to the under-representation in the negative tail of the plot. Differences were considered significant at *p*\<0.05.

Calculation of Effect Sizes {#s2e}
---------------------------

We used the correlation coefficient *r* to index effect sizes. The value of the test statistics resulting from two-tailed *t*-tests, one-way analyses of variance (two groups), chi-squared tests (2×2), and Wilcoxon-Mann-Whitney tests were converted to the correlation coefficient *r* [@pone.0099961-Lipsey1]. In some cases, the value of the test statistic was not reported. In these cases, we calculated the value of the test statistic from the *p*-value and the sample size *n* or the *df* [@pone.0099961-Rosenthal1]. Furthermore, if only the sample means and standard errors of two groups were reported, we calculated a *t*-value from these values. The obtained *r* values indicate how well a particular parameter correlates with the deletion of MCH signaling; an *r* of ±1.0 indicates a perfect (positive/negative) correlation. Correlations are positive when the parameter is suppressed or decreased in the MCH signaling-deficient mice. To estimate the 95% confidence intervals, we transformed the *r* values into Fisher's *z* values. Fisher's *z* is normally distributed, and its variance is 1/(*n*-3). We then calculated the 95% confidence interval the Fisher's *z* metric and converted the Fisher's *z* back to *r*. Statistical analysis was performed using Microsoft Excel.

Analysis of Effect Sizes {#s2f}
------------------------

The mean effect size of each parameter was calculated. In our analyses, the number of experiments that we used to calculate the mean of each parameter was small. Hence, there was not enough power for a test of heterogeneity. We assume that there is one true effect size which is shared by all the included experiments and conducted the analyses using the fixed-effect model [@pone.0099961-Borenstein1]. To calculate the means, we calculated the weighted means of the Fisher's *z*-transformed correlations and converted the results back to the *r* metric. Then, the sample sizes were summed in those parameters. In the overall meta-analysis, significance testing was performed using the 95% confidence intervals. If the confidence interval did not contain zero, we judged the effect of the deletion of MCH signaling on that parameter to be statistically significant. In the separate meta-analyses, we adopted the parameters which were balanced in terms of MCH/MCHR1 KO, background strain, and sex. Further, the mean effect sizes of each group that were judged to be statistically significant were compared with each other using *z*-tests. Differences were considered significant at *p*\<0.05. In the present analysis, the correlations were considered strong when the lower limit of the 95% confidence interval was \>0.3.

Results {#s3}
=======

Publication Bias {#s3a}
----------------

To assess potential publication bias, the tendency that significant results are more likely to be published than negative results, we examined the distributions of the included parameters ([Table 1](#pone-0099961-t001){ref-type="table"}) by funnel plot, showing inverted funnel shapes ([Figure. 2](#pone-0099961-g002){ref-type="fig"}). The Egger tests assessing asymmetry of plotted parameters revealed no significant differences (*p*\>0.05).

In the separate meta-analyses of the MCH and MCHR1 strains, the background strain, and each gender, the distributions of the included behavioral and metabolic parameters ([Tables 2](#pone-0099961-t002){ref-type="table"}--[4](#pone-0099961-t004){ref-type="table"}) exhibited inverted funnel shapes ([Figures. S1](#pone.0099961.s001){ref-type="supplementary-material"}--[3](#pone.0099961.s003){ref-type="supplementary-material"}). The Egger tests revealed no significant differences (*p*\>0.05), which suggests that the results of the separate meta-analyses ([Tables 2](#pone-0099961-t002){ref-type="table"}--[4](#pone-0099961-t004){ref-type="table"}) were relatively robust and that the effects of publication bias were small.

10.1371/journal.pone.0099961.t002

###### Results of meta-analysis in MCH KO or MCHR1 KO mice.

![](pone.0099961.t002){#pone-0099961-t002-2}

  Behavioral/Physiological/Biochemical Parameters    MCH KO   P value vs. MCHR1 KO   MCHR1 KO                                                        
  ------------------------------------------------- -------- ---------------------- ---------- ------- -------- ------ ----- ------- ------- ------- --------
  Body Weight                                          68             0.21            −0.06     0.46     N.S.     \-    124   0.26    0.08    0.43    \<0.05
  Body Weight (High Fat Diet)                          23             0.69             0.36     0.87    \<0.05   N.S.   20    0.54    0.12    0.79    \<0.05
  Fat Mass                                             76             0.67             0.51     0.79    \<0.05   N.S.   44    0.68    0.46    0.82    \<0.05
  Food Intake                                          31            −0.17             0.21     −0.51    N.S.     \-    46    0.01    −0.29   0.31     N.S.
  Food Intake (High Fat Diet)                          45             0.16            −0.16     0.45     N.S.     \-    20    −0.04   0.41    −0.47    N.S.
  Glucose Level                                        21             0.11            −0.33     0.52     N.S.     \-    24    0.21    −0.21   0.56     N.S.
  Insulin Level                                        26             0.07            −0.35     0.47     N.S.     \-    48    0.30    0.01    0.54    \<0.05
  Lean Mass                                            38             0.20            −0.14     0.50     N.S.     \-    16    0.44    −0.07   0.77     N.S.
  Leptin Level                                         16             0.31            −0.29     0.74     N.S.     \-    48    0.77    0.61    0.86    \<0.05
  Locomotor Activity                                   39            −0.21             0.12     −0.51    N.S.     \-    76    −0.13   0.10    −0.35    N.S.
  Locomotor Activity (Dark Phase)                      16            −0.72            −0.29     −0.91   \<0.05   N.S.   32    −0.40   −0.04   −0.67   \<0.05
  Non-REM Sleep (24 h)                                 16             0.82             0.54     0.93    \<0.05   N.S.   32    0.61    0.31    0.80    \<0.05
  Non-REM Sleep (Dark Phase)                           16             0.79             0.48     0.92    \<0.05    \-    16    0.49    −0.01   0.79     N.S.
  Non-REM Sleep (Light Phase)                          16             0.43            −0.09     0.76     N.S.     \-    16    0.49    −0.01   0.79     N.S.
  REM Sleep (24 h)                                     16             0.45            −0.06     0.77     N.S.     \-    16    −0.17   0.36    −0.61    N.S.
  REM Sleep (Dark Phase)                               16             0.34            −0.19     0.71     N.S.     \-    16    −0.17   0.36    −0.61    N.S.
  REM Sleep (Light Phase)                              16             0.24            −0.29     0.65     N.S.     \-    16    −0.17   0.36    −0.61    N.S.
  Wakefulness (24 h)                                   16            −0.84            −0.58     −0.94   \<0.05   N.S.   32    −0.58   −0.27   −0.78   \<0.05
  Wakefulness (Dark Phase)                             16            −0.78            −0.46     −0.92   \<0.05    \-    16    −0.17   0.36    −0.61    N.S.
  Wakefulness (Light Phase)                            16            −0.45             0.06     −0.77    N.S.     \-    16    −0.49   0.01    −0.79    N.S.

r = mean effect size, P value was calculated by Z test.

10.1371/journal.pone.0099961.t003

###### Results of meta-analysis in C57BL/6, 129, or 129×C57BL/6 mice.
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  Behavioral/Physiological/Biochemical Parameters    C57BL/6   P value vs. 129   P value vs. 129×C57BL/6    129    P value vs. 129×C57BL/6   129×C57BL/6                                                                                  
  ------------------------------------------------- --------- ----------------- ------------------------- ------- ------------------------- ------------- ------ ----- ------- ------- ------- -------- ---- ---- ------- ------- ------- --------
  Body Length                                          20           0.43                  −0.01            0.73             N.S.                 \-         \-    22    −0.10   0.33    −0.50    N.S.    \-   \-    \-      \-      \-       \-
  Body Temperature                                     38           −0.50                 −0.20            −0.72           \<0.05                \-        N.S.   \-     \-      \-      \-       \-     \-   30   −0.75   −0.54   −0.88   \<0.05
  Body Weight                                          102          0.54                  0.37             0.67            \<0.05               N.S.        \-    38    −0.49   −0.17   −0.71   \<0.05   \-   \-    \-      \-      \-       \-
  Body Weight (High Fat Diet)                          23           0.69                  0.36             0.87            \<0.05                \-         \-     7    0.54    −0.36   0.92     N.S.    \-   \-    \-      \-      \-       \-
  Corticosterone Level                                 24           0.14                  −0.27            0.52             N.S.                 \-         \-    \-     \-      \-      \-       \-     \-   28   −0.84   −0.66   −0.93   \<0.05
  Elevated Plus Maze                                   106          0.38                  0.19             0.54            \<0.05                \-        N.S.   44    0.08    −0.24   0.38     N.S.    \-   42   0.36    0.05    0.61    \<0.05
  Elevated Plus Maze (Habituated Environment)          40           0.57                  0.30             0.75            \<0.05                \-         \-    44    −0.08   0.24    −0.38    N.S.    \-   \-    \-      \-      \-       \-
  Emergence Test                                       40           −0.58                 −0.31            −0.76           \<0.05                \-         \-    44    −0.14   0.17    −0.43    N.S.    \-   \-    \-      \-      \-       \-
  Emergence Test (Habituated Environment)              40           −0.24                 0.09             −0.52            N.S.                 \-         \-    44    −0.10   0.21    −0.40    N.S.    \-   \-    \-      \-      \-       \-
  Exploratory Behavior                                 40           0.19                  −0.15            0.48             N.S.                 \-         \-    44    0.07    −0.24   0.37     N.S.    \-   \-    \-      \-      \-       \-
  Fat Mass                                             56           0.70                  0.51             0.82            \<0.05               N.S.        \-    23    0.61    0.18    0.84    \<0.05   \-   \-    \-      \-      \-       \-
  Fat Mass (High Fat Diet)                             23           0.71                  0.40             0.88            \<0.05               N.S.        \-     7    0.79    0.10    0.97    \<0.05   \-   \-    \-      \-      \-       \-
  Food Intake                                          31           −0.17                 0.21             −0.51            N.S.                 \-         \-     8    −0.86   −0.39   −0.97   \<0.05   \-   \-    \-      \-      \-       \-
  Food Intake (High Fat Diet)                          45           0.16                  −0.16            0.45             N.S.                 \-         \-     7    −0.66   0.18    −0.94    N.S.    \-   \-    \-      \-      \-       \-
  Ghrelin Level                                        24           0.28                  −0.14            0.61             N.S.                 \-         \-    \-     \-      \-      \-       \-     \-   10   −0.33   0.38    −0.79    N.S.
  Glucose Level                                        23           0.21                  −0.25            0.60             N.S.                 \-         \-     8    0.22    −0.58   0.80     N.S.    \-   \-    \-      \-      \-       \-
  Glucose Level (High Fat Diet)                        37           0.13                  −0.24            0.46             N.S.                 \-         \-     7    0.83    0.20    0.97    \<0.05   \-   \-    \-      \-      \-       \-
  Insulin Level                                         9           −0.30                 0.45             −0.80            N.S.                 \-         \-     8    −0.20   0.59    −0.79    N.S.    \-   \-    \-      \-      \-       \-
  Insulin Level (High Fat Diet)                        23           0.53                  0.11             0.79            \<0.05                \-         \-     7    0.31    −0.58   0.86     N.S.    \-   \-    \-      \-      \-       \-
  Lean Mass                                            38           0.20                  −0.14            0.50             N.S.                 \-         \-     8    0.36    −0.46   0.85     N.S.    \-   \-    \-      \-      \-       \-
  Lean Mass (High Fat Diet)                             9           0.55                  −0.18            0.89             N.S.                 \-         \-     7    −0.46   0.45    −0.90    N.S.    \-   \-    \-      \-      \-       \-
  Leptin Level                                          9           0.43                  −0.33            0.85             N.S.                 \-         \-     8    0.41    −0.41   0.87     N.S.    \-   \-    \-      \-      \-       \-
  Leptin Level (High Fat Diet)                         23           0.66                  0.31             0.85            \<0.05                \-         \-     7    0.60    −0.28   0.93     N.S.    \-   \-    \-      \-      \-       \-
  Leptin Level (per gram fat)                           9           −0.31                 0.44             −0.81            N.S.                 \-         \-     8    0.00    −0.70   0.70     N.S.    \-   \-    \-      \-      \-       \-
  Leptin Level (per gram fat) (High Fat Diet)           9           0.48                  −0.27            0.87             N.S.                 \-         \-     7    0.66    −0.19   0.94     N.S.    \-   \-    \-      \-      \-       \-
  Locomotor Activity                                   39           −0.21                 0.12             −0.51            N.S.                 \-         \-     8    −0.93   −0.66   −0.99   \<0.05   \-   \-    \-      \-      \-       \-
  Locomotor Activity (High Fat Diet)                    8           −0.94                 −0.70            −0.99           \<0.05               N.S.        \-     7    −0.92   −0.55   −0.99   \<0.05   \-   \-    \-      \-      \-       \-
  Locomotor Activity (Dark Phase)                      16           −0.72                 −0.29            −0.91           \<0.05               N.S.        \-     8    −0.91   −0.57   −0.98   \<0.05   \-   \-    \-      \-      \-       \-
  Locomotor Activity (Dark Phase) (High Fat Diet)       8           −0.89                 −0.50            −0.98           \<0.05               N.S.        \-     7    −0.85   −0.27   −0.98   \<0.05   \-   \-    \-      \-      \-       \-
  Motor Coordination                                   100          −0.08                 0.13             −0.28            N.S.                 \-         \-    110   −0.15   0.05    −0.33    N.S.    \-   \-    \-      \-      \-       \-
  Non-REM Sleep (24 h)                                 32           0.61                  0.31             0.80            \<0.05                \-         \-    20    0.05    −0.40   0.48     N.S.    \-   \-    \-      \-      \-       \-
  Non-REM Sleep (Dark Phase)                           16           0.49                  −0.01            0.79             N.S.                 \-         \-    20    0.14    −0.32   0.55     N.S.    \-   \-    \-      \-      \-       \-
  Non-REM Sleep (Light Phase)                          16           0.49                  −0.01            0.79             N.S.                 \-         \-    20    −0.08   0.38    −0.50    N.S.    \-   \-    \-      \-      \-       \-
  Open Field Test                                      160          0.24                  0.09             0.39            \<0.05                \-        N.S.   44    0.06    −0.25   0.36     N.S.    \-   80   0.45    0.26    0.61    \<0.05
  Open Field Test (Habituated Environment)             80           0.46                  0.26             0.63            \<0.05                \-         \-    88    0.16    −0.07   0.36     N.S.    \-   \-    \-      \-      \-       \-
  Oxygen Consumption                                   16           −0.95                 −0.85            −0.99           \<0.05               N.S.        \-     8    −0.98   −0.88   −1.00   \<0.05   \-   \-    \-      \-      \-       \-
  Oxygen Consumption (High Fat Diet)                    8           −0.97                 −0.83            −0.99           \<0.05               N.S.        \-     7    −0.99   −0.95   −1.00   \<0.05   \-   \-    \-      \-      \-       \-
  Response to Handling                                 40           -0.08                 0.25             −0.39            N.S.                 \-         \-    44    0.29    −0.02   0.55     N.S.    \-   \-    \-      \-      \-       \-
  Response to Novelty                                  40           0.26                  −0.07            0.54             N.S.                 \-         \-    44    0.24    −0.07   0.51     N.S.    \-   \-    \-      \-      \-       \-
  Response to Supine Restraint                         20           0.00                  −0.44            0.44             N.S.                 \-         \-    22    0.00    −0.42   0.42     N.S.    \-   \-    \-      \-      \-       \-
  Spatial Learning Function                            20           −0.16                 0.31             −0.56            N.S.                 \-         \-    22    −0.25   0.19    −0.61    N.S.    \-   \-    \-      \-      \-       \-
  Startle Response                                     20           0.15                  −0.31            0.56             N.S.                 \-         \-    22    0.50    0.10    0.76    \<0.05   \-   \-    \-      \-      \-       \-
  Stress Induced Hyperthermia                          22           0.46                  0.05             0.74            \<0.05                \-        N.S.   \-     \-      \-      \-       \-     \-   30   0.78    0.59    0.89    \<0.05
  T4 Level                                             18           0.79                  0.51             0.92            \<0.05                \-        N.S.   \-     \-      \-      \-       \-     \-   24   0.54    0.18    0.78    \<0.05
  Triglyceride Level                                   24           0.55                  0.19             0.78            \<0.05                \-         \-    \-     \-      \-      \-       \-     \-   24   −0.17   0.25    −0.54    N.S.
  Wakefulness (24 h)                                   32           −0.58                 −0.78            −0.27           \<0.05                \-         \-    20    0.07    −0.38   0.50     N.S.    \-   \-    \-      \-      \-       \-
  Wakefulness (Dark Phase)                             16           −0.17                 0.36             −0.61            N.S.                 \-         \-    20    −0.09   0.37    −0.51    N.S.    \-   \-    \-      \-      \-       \-
  Wakefulness (Light Phase)                            16           −0.49                 0.01             −0.79            N.S.                 \-         \-    20    0.22    −0.25   0.60     N.S.    \-   \-    \-      \-      \-       \-

r = mean effect size, P value was calculated by Z test.

10.1371/journal.pone.0099961.t004

###### Results of meta-analysis in male or female mice.
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  Behavioral/Physiological/Biochemical Parameters    Male   P value vs. Female   Female                                                       
  ------------------------------------------------- ------ -------------------- -------- ------- -------- ------ ---- ------- ------- ------- --------
  Body Weight                                        102           0.54           0.37    0.67    \<0.05    \-    52   0.12    −0.17   0.39     N.S.
  Fat Mass                                            87           0.72           0.58    0.81    \<0.05   N.S.   33   0.54    0.23    0.76    \<0.05
  Food Intake                                         46           0.01          −0.29    0.31     N.S.     \-    24   −0.47   −0.08   −0.74   \<0.05
  Food Intake (High Fat Diet)                         22          −0.57          −0.19    −0.80   \<0.05   N.S.   22   −0.51   −0.11   −0.77   \<0.05
  Forced Swim Test                                    34           0.12          −0.23    0.44     N.S.     \-    34   0.34    0.00    0.61    \<0.05
  Glucose Level                                       47           0.14          −0.18    0.43     N.S.     \-    69   0.21    −0.04   0.43     N.S.
  Glucose Level (High Fat Diet)                       10          −0.09           0.57    −0.68    N.S.     \-    10   −0.52   0.16    −0.87    N.S.
  Insulin Level                                       67          −0.03           0.23    −0.29    N.S.     \-    65   0.31    0.05    0.52    \<0.05
  Lean Mass                                           38           0.20          −0.14    0.50     N.S.     \-    20   −0.09   0.37    −0.51    N.S.
  Leptin Level                                        67           0.55           0.33    0.70    \<0.05   N.S.   55   0.60    0.39    0.76    \<0.05
  Leptin Level (per gram Fat) (High Fat Diet)         10           0.55          −0.12    0.88     N.S.     \-    10   0.38    −0.32   0.82     N.S.
  Open Field Test                                     80           0.45           0.26    0.61    \<0.05    \-    34   0.12    −0.23   0.44     N.S.
  T4 Level                                            24           0.54           0.18    0.78    \<0.05    \-    24   0.25    −0.17   0.60     N.S.
  Triglyceride Level                                  24           0.14          −0.27    0.52     N.S.     \-    24   −0.17   0.25    −0.54    N.S.

r = mean effect size, P value was calculated by Z test.

Overall Meta-analysis: Comparison of the Effects of MCH Signaling on Phenotypes {#s3b}
-------------------------------------------------------------------------------

The effects of MCH signaling on behavioral and metabolic parameters are summarized in [Table 1](#pone-0099961-t001){ref-type="table"}. Overall, the meta-analysis revealed that the deletion of MCH signaling suppressed non-REM sleep, anxiety, response to novelty, startle response, stress-induced hyperthermia, conditioned place preference, and olfaction (*p*\<0.05) and that MCH signaling deficiency enhanced locomotor activity, wakefulness, alcohol preference, motor activation by psychostimulants, aggression, male sexual behavior, and social interaction (*p*\<0.05).

Regarding the metabolic parameters, the deletion of MCH signaling suppressed body weight, fat mass, leptin level, liver triglyceride level, and total cholesterol level (*p*\<0.05), and MCH signaling deficiency enhanced food intake, body temperature, oxygen consumption, heart rate, mean arterial pressure, corticosterone level, and norepinephrine transporter level in the globus pallidus and nucleus accumbens (*p*\<0.05). Additionally, MCH-signaling deficiency decreased D~1~ receptor levels in the nucleus accumbens and the ventral tegmental area, D~2~ receptor levels in the caudate-putamen and olfactory tubercle, NR1 subunit levels in the hippocampal formation, and 5-HT levels in the prefrontal cortex (*p*\<0.05).

Strong correlations (95% confidential interval lower limit\>0.3) were observed among the parameters related to body-weight regulation, including oxygen consumption, body temperature, fat mass, heart rate, arterial pressure, plasma leptin, locomotor activity, and serum total cholesterol. Other parameters that exhibited strong correlations (95% confidence interval with a lower limit\>0.3) were non-REM sleep time, wake time, stress-induced hyperthermia, aggression, male sexual behavior, 5-HT levels in the prefrontal cortex, and norepinephrine transporter levels in the globus pallidus.

We did not find any inconsistency in the effect size between the earlier literatures before 2002 and recent literatures published in 2005 and later. For example, glucose level of MCH-deficient mouse reported in 1998 [@pone.0099961-Shimada1], is consistent with that reported in 2005 [@pone.0099961-Kokkotou1].

Separate Meta-analyses for MCH Deficiency or MCHR1 Deficiency {#s3c}
-------------------------------------------------------------

The different effects of MCH deficiency and MCHR1 deficiency on the behavioral and metabolic parameters are summarized in [Table 2](#pone-0099961-t002){ref-type="table"}. Separate meta-analyses for the deficiencies of the ligand and receptor revealed that both MCH deficiency and MCHR1 deficiency suppressed the body weight when the mice were on a high-fat diet, the fat mass, and the non-REM sleep time, whereas both MCH-deficient mice and MCHR1-deficient mice exhibited increased wake times and locomotor activities during the dark phase (*p*\<0.05). MCHR1 deficiency produced significant effects on body weight, plasma insulin, and plasma leptin, and the MCH-deficient mice did not exhibit any significant effects in these parameters.

Separate Meta-analyses by Background Strain {#s3d}
-------------------------------------------

Behavioral studies of MCH and MCHR1 deficiency were performed using mice of the C57BL/6 (B6), 129/Sv (129), and 129-B6 mixed (mixed) backgrounds. Because each strain has different behavioral and metabolic characteristics due to genetic variations, the phenotypes of the gene-modified mice may vary among the different strains. Nevertheless, the phenotypes to which alterations in MCH signaling mainly contribute are thought to be recognizable in MCH signal-deficient mice of different strains. The results of the separate meta-analyses of the effects of the MCH and MCHR1 deficiencies on the behavioral and metabolic parameters are summarized in [Table 3](#pone-0099961-t003){ref-type="table"}. In both the 129 and B6 backgrounds, the MCH and MCHR1 deficiencies decreased fat mass and increased oxygen consumption and locomotor activity (*p*\<0.05). Interestingly, significant increases in food intake and body weight in the MCH-deficient mice were found only in the 129 (*p*\<0.05) and not in the B6 background. The deletion of MCH signaling increased body temperature in the B6 and mixed backgrounds (*p*\<0.05) and suppressed stress-induced hyperthermia in the B6 and mixed backgrounds (*p*\<0.05). Due to the small number of studies that used mixed-background mice, data regarding body weight, fat mass, oxygen consumption, locomotor activity, and food intake were not available.

Under a high-fat diet, the deficiency in MCH signaling reduced the fat mass and increased oxygen consumption in both the 129 and B6 backgrounds (*p*\<0.05). The lack of MCH signaling exhibited a suppressive effect on glucose levels under a high-fat diet only in the 129 mice (*p*\<0.05), and no significant effect was observed in the B6 mice. Strain-specific effects were also observed in the following parameters: anxiolytic effects, as assessed with an open field test and elevated plus maze test, were observed in the MCH-deficient mice of both the B6 and mixed backgrounds (*p*\<0.05), whereas no significant effects were observed in the 129 background mice; MCH-signaling deficiency in the B6 background produced a significant increase in wake time and a significant decrease in non-REM sleep time, and MCH-signaling deficiency in the 129 background did not produce significant changes in sleep/wakefulness behaviors.

Separate Meta-analyses by Sex {#s3e}
-----------------------------

To examine the differential role of MCH signaling in males and females, we performed separate meta-analyses, which are summarized in [Table 4](#pone-0099961-t004){ref-type="table"}. MCH or MCHR1 deficiency suppressed fat mass and plasma leptin and enhanced high-fat diet intake in both sexes (*p*\<0.05). The deletion of MCH signaling in the male mice suppressed body weight, anxiety, and plasma T4 (*p*\<0.05). The deletion of MCH signaling in the female mice suppressed depressive behavior and plasma insulin (*p*\<0.05) and enhanced food intake (*p*\<0.05).

Discussion {#s4}
==========

The Role of MCH Signaling in Feeding Behavior {#s4a}
---------------------------------------------

Nearly two decades ago and long after the report of the expression of MCH in the mammalian lateral hypothalamus [@pone.0099961-Skofitsch1], Qu et al. reported the orexigenic effect of MCH [@pone.0099961-Qu1]. Because the lateral hypothalamus is known to be a "feeding center" [@pone.0099961-Anand1], the orexigenic effects of MCH received much attention that resulted in numerous reports that used MCH and MCH receptor antagonists [@pone.0099961-Rossi1], [@pone.0099961-Takekawa1], [@pone.0099961-Borowsky1]. Consistent with these pharmacological studies, the first report of MCH-deficient mice found a mild reduction in food intake [@pone.0099961-Shimada1]. However, later reports failed to reproduce this hypophagia in MCH signaling-deficient mice [@pone.0099961-Kokkotou1], [@pone.0099961-Astrand1].

Surprisingly, the present meta-analysis revealed that MCH-signaling deficiency caused mild but significant increases in food intake when the mice were given normal or high-fat diets. However, the separate analyses of the MCH-deficient mice and the MCHR1-deficient mice did not show such an effect. The combined meta-analysis of the ligand- and receptor-deficient mice had sufficient statistical power to detect mild hyperphagia in the MCH signaling-deficient mice. The increased food intake of the MCH signaling-deficient mice does not contradict the acute orexigenic effects of MCH that have been reported by independent researchers based on pharmacological experiments [@pone.0099961-Qu1], [@pone.0099961-Rossi1], [@pone.0099961-Takekawa1], [@pone.0099961-Borowsky1]; rather, these effects suggest that the acute orexigenic effects of MCH may be cancelled by long-term body-weight homeostasis mechanisms. For example, the administration of orexin, another orexigenic peptide that is expressed in the lateral hypothalamus, results in increased food intake in acute experiments but not in chronic injection experiments [@pone.0099961-Sakurai1], [@pone.0099961-Yamanaka1]. Moreover, the overexpression of orexin renders mice resistant to diet-induced obesity [@pone.0099961-Funato1], which suggests that short-term feeding behaviors and long-term body-weight homeostasis are regulated by distinct mechanisms.

MCH Signaling Regulates Body Weight Homeostasis {#s4b}
-----------------------------------------------

Our meta-analysis confirmed that the body weights were reduced and that oxygen consumption increased in the MCH signaling-deficient mice on both normal chow and high-fat diets. Thus, the lean phenotype of the MCH signaling-deficient mice is likely due to increased energy output and not due to reduced energy input. The increased food intake of the MCH signaling-deficient mice may be caused by feedback regulation that maintains stable body weights. Consistent with this notion, our meta-analysis revealed that the MCH signaling-deficient mice exhibited decreased plasma leptin levels; leptin is a major anorexigenic hormone that is secreted from adipose tissues. Suppressive effects of MCH signaling deficiency on the weight gains of mice on high-fat diets were also found in the separate meta-analyses of the MCH-deficient, MCHR1-deficient, B6, male, and female mice. The lack of a suppressive effect on diet-induced obesity in the 129 background may have resulted from the fact that the wild-type 129 strain is resistant to diet-induced obesity, which, due to a floor effect, would make it difficult to observe a suppressive effect on body-weight gain [@pone.0099961-Kokkotou1].

The major source of energy output in rodents is the brown adipose tissue; the thermogenic activity of this tissue is regulated by the sympathetic nervous system [@pone.0099961-Cannon1]. Consistently, MCH neurons provide polysynaptic projections to the sympathetic nervous system and the skeletal muscle [@pone.0099961-Kerman1]. The loss of MCH signaling results in enhanced sympathetic tone, which increases energy output. The increased heart rates and higher arterial pressures in the MCH signaling-deficient mice also support the presence of enhanced sympathetic tone. The stress-induced hyperthermia of the MCH signaling-deficient mice may be partly due to the enhanced activity of the sympathetic nervous-brown adipose tissue system [@pone.0099961-Nakamura1]. The present meta-analysis also revealed increased locomotion in the MCH signaling-deficient mice on both normal chow and high-fat diets; this increased locomotion would also contribute to energy output via skeletal muscle activity.

MCH Signaling Regulates Sleep/Wakefulness Behavior {#s4c}
--------------------------------------------------

MCH neurons are actively firing during non-REM sleep and are more active during REM sleep. Our meta-analysis confirmed that MCH signaling deficiency enhanced wakefulness, suppressed non-REM sleep, and did not alter REM sleep. Because MCH neurons project to the locus coeruleus [@pone.0099961-Saito2], which is crucial for wakefulness [@pone.0099961-Carter1], [@pone.0099961-Monti1], the loss of the inhibitory input of the MCH neurons onto the locus coeruleus may result in enhanced wakefulness.

The lack of a significant effect on REM sleep seems to be inconsistent with the fact that the highest activity levels of the MCH neurons occur during REM sleep [@pone.0099961-Hassani1]. However, the optogenetic activation of MCH neurons in MCHR1-deficient mice enhances REM sleep [@pone.0099961-Jego1], which suggests that the MCH peptide released from the MCH neurons is not crucial for the generation of REM sleep.

MCH Signaling Regulates Anxiety and Stress Responses {#s4d}
----------------------------------------------------

There have been contradictory reports about the anxiety-related behavior of MCH signaling-deficient mice [@pone.0099961-Lalonde1], [@pone.0099961-Roy1], [@pone.0099961-Adamantidis1], [@pone.0099961-Roy2], [@pone.0099961-Tyhon2]. Our meta-analysis did not produce clear conclusions regarding the effects of MCH signaling deficiency on anxiety; weak anxiolytic effects were found for in the elevated plus maze and open field tests, but weak anxiogenic effects were found in the emergence test. The increased plasma corticosterone levels during non-stressed conditions observed in the MCH signaling-deficient mice suggest that the activity of the hypothalamic-pituitary-adrenal (HPA) axis is enhanced and that these mice should tend to exhibit anxiogenic behavior [@pone.0099961-DeKloet1]. Consistent with the enhanced activity of the HPA axis, the MCH signaling-deficient mice exhibited increased stress-induced hyperthermia, startle responses, and responses to novelty.

The Role of MCH Signaling in Reward-seeking Behavior and Addiction {#s4e}
------------------------------------------------------------------

MCHR1 is most strongly expressed in the nucleus accumbens [@pone.0099961-Saito2], which, along with the midbrain dopamine neurons, constitutes the neural circuitry that regulates reward-seeking behavior and addiction. Consistently, our meta-analysis revealed that the MCH signaling-deficient mice exhibited decreased cocaine-induced conditioned place preferences, which suggests that the MCH signaling-deficient mice are resistant to drug addiction. The increased locomotion of the MCH-deficient mice may have resulted from alterations in the mesolimbic dopamine system. Alterations in the dopaminergic system may also be involved in the hyperphagia exhibited by the MCH signaling-deficient mice. Although MCH signaling-deficient mice exhibit increased alcohol intake and a seemingly contradictory resistance to psychostimulants, the molecular target of alcohol in the brain is not the dopamine transporter but the GABA A receptor [@pone.0099961-Tabakoff1]. Thus, the neural substrates of alcohol-seeking behavior are thought to be distinct from those related to addictive behavior associated with dopamine-related psychostimulants`.`

MCH Signaling Regulates Aggression and Sexual Motivation {#s4f}
--------------------------------------------------------

The present meta-analysis revealed that MCH-signaling deficiency was strongly correlated with enhanced aggression and male sexual behavior (*r* = −0.704 and *r* = −0.832, respectively). MCHR1 is expressed in the ventromedial nucleus of the hypothalamus [@pone.0099961-Saito2], which contains neurons that are involved in attack behavior and male sexual behavior [@pone.0099961-Lin1], [@pone.0099961-Anderson1]. MCHR1 expression in the medial amygdala also plays an important role in aggression [@pone.0099961-Nelson1]. Defects in the olfactory system of MCH-deficient mice might be involved in the alterations of aggression and male sexual behavior [@pone.0099961-Adams1].

Therapeutic Implications {#s4g}
------------------------

Based on an anorexic effect of the MCH peptide and the lean phenotypes of the MCH-deficient and MCHR1-deficient mice, MCHR1 antagonists have been recognized as attractive targets for the treatment of obesity. Continued efforts to develop small compounds that antagonize MCH signaling have extended the list of MCHR1 antagonists; some of these antagonists have been examined in clinical trials [@pone.0099961-Takekawa1], [@pone.0099961-Borowsky1], [@pone.0099961-Shearman1]--[@pone.0099961-Moore1]. The current meta-analysis suggests that in addition to the treatment of obesity, possible therapeutic targets of MCHR1 antagonists include anxiety disorder, depressive disorder, hypersomnia, sleepiness, male sexual dysfunction, drug addiction, and hypotension. The possible side effects of the clinical use of MCHR1 antagonists include insomnia, hypersexuality, aggression, and hypertension.

The prominent difference in MCH signaling between humans and rodents is that humans express MCHR2. Although MCHR2 is expressed in the brain in a pattern similar to that of MCHR1, the downstream target of MCHR2 is different from that of MCHR1 because MCHR2 is a Gq-coupled receptor, whereas MCHR1 is a Gi-coupled receptor [@pone.0099961-An1]--[@pone.0099961-Sailer1]. Thus, it is difficult to predict the clinical effects of MCHR1 antagonists in humans without an understanding of the physiological role of MCHR2 signaling. Indeed, a phase I clinical trial of an MCHR1 antagonist was discontinued due to the vivid dreams experienced by the subjects during the first week of treatment (NGD-4715; <http://phx.corporate-ir.net/phoenix.zhtml?c=>). This result could not be predicted based on the suppression of REM sleep following the injection of MCHR1 antagonists or the normal REM sleep of the MCH signaling-deficient mice.

Limitations and Strengths {#s4h}
-------------------------

Studies that utilized mice in which the MCH neurons were ablated with ataxin-3 or diphtheria toxin were excluded from our meta-analysis because the lack of the GABAergic neurotransmission of the MCH neurons may result in behavioral alterations that are independent of the MCH-MCHR1 signal. Nevertheless, MCH neuron-ablated mice are lean and exhibit increased oxygen consumption, hyperlocomotion, and reduced responses to cocaine; these phenotypes are consistent with the results of the current meta-analysis of MCH signaling-deficient mice [@pone.0099961-Alon1], [@pone.0099961-Whiddon1].

The present meta-analysis is not free of limitations. The sample sizes varied across the parameters: many of the included studies examined body weight and food intake, but few studies examined oxygen consumption, largely because a special experimental apparatus is required to measure and control oxygen and carbon dioxide levels to allow for indirect calorimetry. The numbers of studies that we used to calculate the means of each parameter were small. Hence, there was not enough power for a test of heterogeneity. Furthermore, the number of parameters used for separate meta-analysis was small because we adopted the parameters which were balanced in terms of genotypes, sex, and strains.

To the best of our knowledge, the present work is the first study to systematically compare the effects of MCH signaling on behavioral and metabolic phenotypes. Our analyses revealed the robust contribution of MCH signaling to energy metabolism, reward behavior, and anxiety. Large numbers of researchers and international consortia are working on phenotyping genetically modified mice [@pone.0099961-Brown1], and in combination with the remarkable progress that has been made in genome-editing techniques, this work has rendered the production of genetically modified mice easier and faster. Thus, the amounts of behavioral and metabolic data related to genetically modified mice will continue to increase. To obtain relevant conclusions from these large datasets, meta-analyses will become increasingly important in basic biomedical research.

Supporting Information {#s5}
======================
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**Funnel plot of effect sizes against sample sizes in separate meta-analysis by ligand-receptor.** Black circles indicate behavioral or metabolic parameters in MCH KO (left panel) or MCHR1 KO mouse (right panel).

(TIF)
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Click here for additional data file.
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**Funnel plot of effect sizes against sample sizes in separate meta-analysis by background strain.** Black circles indicate behavioral or metabolic parameters in C57BL/6 (left panel), 129 (middle panel), or 129×C57BL/6 mouse (right panel).

(TIF)
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Click here for additional data file.
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**Funnel plot of effect sizes against sample sizes in separate meta-analysis by sex.** Black circles indicate behavioral or metabolic parameters in male (left panel) or female mouse (right panel).

(TIF)
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Click here for additional data file.

###### 

**A descriptive summary of the studies used in the meta-analysis.**
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PRISMA Checklist.
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